Environmental factors such as maternal stress, traumatic brain injury, psychosocial stress, and drug abuse can instigate psychosis [1]. Among these factors, it has been shown in multiple studies that drug use can lead to psychosis without the involvement of genetic factors, especially in adult animals [2-6]. The representative drugs that can cause psychosis are amphetamine, scopolamine, ketamine, phencyclidine (PCP), and lysergic acid diethylamide (LSD) [7]. Specifically, psychosis induced by amphetamine had shed light on schizophrenia studies by transitioning the focus on psychoanalytic perspectives to the neurotransmitter perspective [8]. This relationship between drug induced psychosis (DIP) and schizophrenia has allowed researchers to utilize drugs in studying neurotransmitter roles in schizophrenia. Therefore, DIP animal models were frequently considered as schizophrenia animal models [9].

However, despite the use of DIP as a schizophrenia model, whether DIP animal models are the ideal schizophrenia models has yet to be determined. In addition, causality between drug use and psychosis cannot be established. The varying dosage and regimen of administration of drugs such as amphetamine, scopolamine, PCP, ketamine, and LSD are essential factors for inducing psychosis. On the other hand, schizophrenia is dominantly determined via genetic factors, and DIP is dependent on acquired environmental factors. Involvement of genetic factors...
Amphetamine induced psychosis

Amphetamine was first synthesized in 1887, and was used as a stimulant to promote the performance of soldiers during World War II. Ever since its addictive properties have been found, its use was only limited to medical use. Despite strict regulations, the number of people with amphetamine induced psychosis (AIP) along with the excessive use of amphetamine has increased.

With the increase in the number of people with AIP, studies have been conducted to establish an AIP animal model, which has been further stimulated by the fact that the symptoms of AIP are similar to the symptoms of schizophrenia. According to AIP studies, temporal amphetamine administration did not produce psychosis but significant administration of amphetamine induced psychoses limited to only positive and cognitive symptoms (Table 1). Specifically, sub-chronic amphetamine administration into healthy adult rats produced amphetamine sensitization, disrupted latent inhibition, and decreased attentional vigilance, of which its effect lasted for 90 days after the last injection (Table 2) [12-14]. Also, although deficits in the attention set-shifting task were observed, spatial memory was not impaired in the Morris water maze, indicating that cognitive impairments in the AIP model appeared to be restricted to some prefrontal cortex (PFC) dependent tasks [15, 16]. Another protocol for AIP is a chronic and incremental dosage administration schedule of amphetamine, where the psychotogenic effect of this regimen is not extensively different with sub-chronic schedule (Table 2).

These psychotic symptoms within the positive and cognitive classifications were explained by the molecular function of amphetamine. Amphetamine increases the dopamine level in the synaptic cleft via inhibition of dopamine reuptake into the presynaptic neuron and facilitation of the release of vesicles containing dopamine (Fig. 1). Therefore, it has been accepted as the most plausible explanation of AIP. Amphetamine administration causes an overflow of dopamine in the striatum, which leads to excessive glutamate release into the cortex. Excess glutamate in the cortex may, over time, cause damage to cortical interneurons [7, 17]. The increase of dopamine in the striatum and the increase of glutamate in the cortex explain the positive and cognitive symptoms, respectively. On the other hand, this explanation of how molecular function of amphetamine affects psychotic behaviors has also been examined by antipsychotic drugs. The representative typical and atypical antipsychotics are haloperidol and clozapine, respectively. Haloperidol is a dopamine D2 antagonist, and clozapine is a 5-HT agonist, dopamine D2 receptor antagonist, muscarinic antagonist of the M1, M2, M3, M5 subtypes, agonist of the M4, and agonist at the glycine site of the NMDA receptor. Locomotor sensitization and latent inhibition of
Drug Induced Psychosis

AIP was alleviated by both of these antipsychotics [18], whereas amphetamine-induced working memory impairment was improved by the clozapine, but not haloperidol [9, 19]. Although the effects of these antipsychotics may provide that positive symptoms resulted from increased dopamine, it is still not enough to explain the direct link between amphetamine and psychotic symptoms.

Despite the absence of a direct link, it is obvious that a specific amphetamine administration regimen can induce positive and cognitive symptoms, but not negative symptoms. It is because of this lack of negative symptoms that the AIP model is insufficient as an ideal schizophrenia model. In addition, it is notable that psychosis can be induced by amphetamine injection into non-transgenic animals or healthy animals whose breeding environment was not stressful, suggesting that drug abuse is sufficient to induce psychosis independently without the involvement of the genetic component of schizophrenia.

Scopolamine induced psychosis

Unlike the majority of drugs discussed in this literature, scopolamine lacks addictive properties. Rather, it is a major component of medications that treat motion sickness. However, administration of scopolamine in patients elicits prominent side effects such as hallucinations, delusions, and memory deficits. There has been an increasing effort to establish a scopolamine induced psychosis (SIP) animal model, primarily owing to the observation of muscarinic antagonists such as atropine and scopolamine inducing psychosis, and investigation into the alleviation of cognitive symptoms of schizophrenia by cholinergic stimulation.

To model SIP in animals, multiple behavioral studies have used acute injection regimens of scopolamine (Table 2). In each of these studies, disrupted behavior was found to be consistent with that of the positive, negative, and cognitive symptom categories of psychosis. For instance, behavioral changes such as impaired prepulse inhibition/latent inhibition, social recognition deficit, and working memory deficit were representative of positive, negative,
Table 2. Administration protocols of psychosis animal model of amphetamine, scopolamine, PCP/ketamine and LSD in rats and mice

| Drug              | Dose                                                                 | Duration | Strain          | Behavior test                                                                 | Reference |
|-------------------|----------------------------------------------------------------------|----------|-----------------|-------------------------------------------------------------------------------|-----------|
| Amphetamine       | Sub-chronic and incremental dosage schedule                         | 90 day   | Wistar rats     | Amphetamine sensitization (1 mg/kg challenge)                                 | [14]      |
|                   | 3 injections (06:00, 12:00, and 18:00)/day for 6 days                |          |                 |                                                                                |           |
|                   | Day 1 – 1 mg/kg, 2 mg/kg, and 3 mg/kg                               |          |                 |                                                                                |           |
|                   | Day 2 – 4 mg/kg, 5 mg/kg, and 5 mg/kg                               |          |                 |                                                                                |           |
|                   | Day 3–6 – 5 mg/kg, 5 mg/kg, and 5 mg/kg                             |          |                 |                                                                                |           |
|                   | 3 injections (08:00, 14:00, and 20:00)/day for 6 days                | 28 day   | Wistar rat/Male | Disrupted latent inhibition                                                    | [12]      |
|                   | Day 1 – 1 mg/kg, 2 mg/kg, and 3 mg/kg                               |          |                 |                                                                                |           |
|                   | Day 2 – 4 mg/kg, 5 mg/kg, and 5 mg/kg                               |          |                 |                                                                                |           |
|                   | Day 3–6 – 5 mg/kg, 5 mg/kg, and 5 mg/kg                             |          |                 |                                                                                |           |
|                   | Chronic and incremental dosage schedule                              | 22 day   | Sprague – Dawley rat/Male                        | Disrupted PPI and amphetamine sensitization (3 mg/kg challenge)                | [2]       |
|                   | Once daily for 3 times (Monday, Wednesday, and Friday) for a week    |          |                 |                                                                                |           |
|                   | Week 1 – 1 mg/kg                                                    |          |                 |                                                                                |           |
|                   | Week 2 – 2 mg/kg                                                    |          |                 |                                                                                |           |
|                   | Week 3 – 3 mg/kg                                                    |          |                 |                                                                                |           |
|                   | Once daily, 3 times (Monday, Wednesday, and Friday) for a week       |          |                 |                                                                                |           |
|                   | Week 1 – 1 mg/kg                                                    |          |                 |                                                                                |           |
|                   | Week 2 – 2 mg/kg                                                    |          |                 |                                                                                |           |
|                   | Week 3 – 3 mg/kg                                                    |          |                 |                                                                                |           |
|                   | Week 4 – 4 mg/kg                                                    |          |                 |                                                                                |           |
|                   | Week 5 – 5 mg/kg                                                    |          |                 |                                                                                |           |
| Scopolamine       | Acute schedule                                                       | <1 day   | Wistar rat/Male | Disrupted latent inhibition                                                    | [3]       |
|                   | 0.15 and 0.5 mg/kg                                                  |          |                 | Social recognition deficit in 3-chamber test                                  | [20]      |
|                   | 0.3 and 0.5 mg/kg                                                  |          | C57BL/6J mouse/Female                             | Working memory deficit (T-maze spontaneous alteration)                         | [85]      |
|                   | 0.3, 1, 2, and 3 mg/kg                                             | <1 day   | CD-1 mouse/Male                                     | PPI impairment                                                                 | [21]      |
|                   | 10 mg/kg                                                            | <1 day   | C57BL/6NCrl mice/male                              | Hyperlocomotion and excessive fear (latency time of fear conditioning was increased) | [4]       |
| Ketamine          | Acute schedule                                                       | <1 day   | Swiss mouse/Male                                    | Working memory deficit                                                         | [35]      |
|                   | 100 mg/kg                                                           |          |                 | Hyperlocomotion                                                               | [89]      |
|                   | Sub-chronic schedule                                                | 21 day   | Hooded Lister rat/Male                              | Increased immobility time in forced swim test                                 | [86]      |
|                   | Once daily for 5 days                                               | 10 day   | Wistar rat/Male                                     | Hyperlocomotion                                                               | [89]      |
|                   | 10 mg/kg                                                            |          |                 | Working memory deficit (Mismatch detection test)                              |           |
|                   | 30 mg/kg                                                            |          |                 | Hyperlocomotion, increased immobility time in forced swim test, and increased latency time of fear conditioning | [4]       |
|                   | Once daily for 5 days                                               |          |                 |                                                                                |           |
|                   | 30 mg/kg                                                            |          |                 |                                                                                |           |
|                   | 2 injection for 6 days                                              | 10 day   | Long Evans rat/Male                                 |                                                                                |           |
|                   | 30 mg/kg                                                            |          |                 |                                                                                |           |
|                   | Chronic schedule                                                    | 11 day   | Swiss mouse/Male                                    |                                                                                |           |
|                   | Once daily for 10 days                                              |          |                 |                                                                                |           |
|                   | 100 mg/kg                                                           |          |                 |                                                                                |           |
Drug Induced Psychosis

Scopolamine is a non-selective antagonist of muscarinic acetylcholine receptors and binds to a group of muscarinic receptors (M1-M5) which directly modulates the release of acetylcholine or indirectly of dopamine. These receptors are classified into M1-like muscarinic receptors (M1, M3, M5) and M2-like receptors, (M2, M4) which activate and inhibit second messenger transduction via G-proteins respectively [22, 23]. Specifically in the mesopontine nuclei, scopolamine blockade of the M2 muscarinic auto-receptor in the axon terminal is suggested to elevate acetylcholine levels in the midbrain areas of substantia nigra (SN) and ventral tegmental area (VTA), thus eliciting an increment in the striatal dopaminergic levels (Fig. 1) [24, 25]. Such activity may lead to positive symptoms of psychosis such as hyperactivity and stereotypy [26, 27]. Whereas, inhibition of M4 subtype receptors is suggested to result in cognitive deficits in memory and attention [22]. Negative symptoms of SIP can be indirectly explained by the effect of antipsychotics. Clozapine in particular was found to reverse social recognition deficit [21]. Donepezil, a cholinesterase inhibitor, was also known to restore social recognition deficit.

Table 2. Continued

| Drug  | Dose               | Duration | Strain            | Behavior test                                      | Reference |
|-------|--------------------|----------|-------------------|----------------------------------------------------|-----------|
| PCP   | Acute schedule     | 5 mg/kg  | <1 day            | Hyperlocomotion                                    | [32]      |
|       |                    | 2.58 mg/kg| <1 day            | Attentional set-shifting deficit (Extra dimensional shift) | [33]      |
|       |                    | 1.5 mg/kg| <1 day            | Hyperlocomotion, stereotype behavior, and reduced social interaction | [87]      |
|       | Sub-chronic schedule| 2 injection (0800 2000) for 7 days | 5 mg/kg | 10 day | Long-Evans rat | Hyperlocomotion and reduced social interaction | [5]        |
|       | Chronic schedule   | 5 mg/kg  | <1 day            | Hyperlocomotion and disrupted working memory | [5]        |
|       |                    | 0.03, 0.1, and 0.3 mg/kg | <1 day | Wistar Rats/ Male | Hyperlocomotion and disrupted PPI | [43]      |
|       | Acute schedule     | 0.1 and 0.3 mg/kg | <1 day | Sprague-Dawley Rats | Hyperlocomotion and disrupted PPI | [43]      |
|       | Chronic schedule   | 0.16 mg/kg| 1 month | Sprague-Dawley rat/ Male | Hyperlocomotion, decreased social behavior, and anhedonia | [6, 42]  |
|       |                    | 5 mg/kg  | <1 day            | Attentional set-shifting deficit (Extra dimensional shift) | [34]      |
|       |                    | 5 mg/kg  | <1 day            | Hyperlocomotion and disrupted working memory | [5]        |
|       |                    | 5 mg/kg  | <1 day            | Hyperlocomotion and disrupted working memory | [5]        |
|       |                    | 5 mg/kg  | <1 day            | Hyperlocomotion and disrupted working memory | [5]        |
|       |                    | 5 mg/kg  | <1 day            | Hyperlocomotion and disrupted working memory | [5]        |
| LSD   | Acute schedule     | 0.03, 0.1, and 0.3 mg/kg | <1 day | Wistar Rats/ Male | Hyperlocomotion and disrupted PPI | [43]      |
|       | Chronic schedule   | 0.1 and 0.3 mg/kg | <1 day | Sprague-Dawley Rats | Hyperlocomotion and disrupted PPI | [43]      |
|       |                    | 0.16 mg/kg| 1 month | Sprague-Dawley rat/ Male | Hyperlocomotion, decreased social behavior, and anhedonia | [6, 42]  |
|       |                    | 0.03, 0.1, and 0.3 mg/kg | <1 day | Wistar Rats/ Male | Hyperlocomotion and disrupted PPI | [43]      |
|       |                    | 0.1 and 0.3 mg/kg | <1 day | Sprague-Dawley Rats | Hyperlocomotion and disrupted PPI | [43]      |
|       |                    | 0.16 mg/kg| 1 month | Sprague-Dawley rat/ Male | Hyperlocomotion, decreased social behavior, and anhedonia | [6, 42]  |

PCP, phencyclidine; LSD, lysergic acid diethylamide; PPI, prepulse inhibition.

This table includes the drug, administration protocol, time taken behavioral experiments after administration of the drug, strain, and psychotic behaviors that was determined by each administration protocol. The administration protocol for 10 days or less was marked as a sub-chronic schedule, and administration protocol for over 10 days was marked as a chronic schedule. In the case of behavioral testing on the day of drug administration, it was labeled as occurring for less than 1 day.
PCP/ketamine induced psychosis

PCP was developed as a dissociative anesthetic agent for surgical operations in the 1950s. It is now only used in the veterinary field and is not used on humans due to its side effects. The side effects include delirium, unconsciousness, hallucinations, depression, and memory loss, which are similar to psychoses of positive and negative categories. As a result of these side effects of PCP, ketamine has been developed as a substitute for the PCP [29]. However, ketamine has also proved to have a psychotogenic effect. Although the psychotogenic effect of PCP is much stronger than that of ketamine, both drugs share similarities in the administration regimens for producing psychosis due to the fact that both drugs are NMDA receptor antagonists and share binding sites within the NMDA receptor. Thus, PCP induced psychosis (PIP) and ketamine induced psychosis (KIP) are discussed together below.

Unlike amphetamine, acute PCP and ketamine administrations are sufficient to induce psychosis in healthy people as well as in animals [4, 30, 31]. Acute ketamine administration of animals leads to hyper-locomotion when the injected animals are exposed to a novel environment [4]. On the other hand, PCP induces a more powerful psychotic response relative to ketamine. Acute
PCP administration into animals produces hyper-activity, reduced social interaction, and decreased cognitive flexibility, and these symptoms are also shown with sub-chronic and chronic PCP administration regimens (Table 2) [9, 5, 32-34]. In KIP models using sub-chronic and chronic regimens, symptoms similar to those observed in the acute PCP model are also shown [4, 35].

As negative symptoms that were not observed in the AIP animal model were induced by PCP and ketamine, the mechanism explaining negative symptoms emerged based on the understanding that PCP and ketamine are uncompetitive antagonist of the NMDA receptor. Based on the inhibition of GABAergic interneuron in the prefrontal cortex by these antagonists, increased neuronal activity and excessive glutamate in the glutamatergic neuron of the PFC were mainly considered as the neurobiological explanation for the negative symptoms (Fig. 2) [31, 36]. The molecular function of PCP/ketamine that affects psychotic behaviors has also been examined by antipsychotic drugs. Hyper-locomotion induced by acute ketamine administration was reversed by haloperidol, clozapine, and risperidone [4]. Risperidone is an antagonist of dopamine D2 and 5-HT2A receptors, and has affinity for various receptors such as the dopamine D1 receptor, adrenergic receptors, and histamine.

**Fig. 2.** PCP, Ketamine and LSD alter glutamate neurotransmission. (A) PCP and ketamine regulate glutamate transmission. They bind to NMDA receptors of the PFC GABAergic interneuron. The NMDA receptor hypofunction on GABAergic neurons induces hyper-glutamatergic transmission. (B) LSD affects serotonergic transmission and glutamate transmission. LSD binds to the 5-HT2A receptor located on thalamus glutamatergic neurons where serotonergic raphe neurons send efferent projections. Glutamate release of thalamic neuron is increased due to the effect of LSD, resulting in hyper glutamatergic transmission in the PFC. The upper orange neuron indicates presynaptic glutamatergic neuron whereas lower orange neuron indicates a postsynaptic neuron. The yellow neuron of figure (A) denotes GABAergic interneuron in the PFC and that of figure (B) denotes thalamic glutamatergic neuron. The green neuron is a serotonergic neuron in the raphe nucleus. AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; NMDAR, N-methyl-D-aspartate receptor; GABAR, gamma-Aminobutyric acid receptor; 5-HT2AR, serotonin 2A receptor.
receptors [37]. Haloperidol was ineffective on cognitive deficits in behavioral tests such as set-shifting task, reversal learning, and novel object recognition in the sub-chronic PIP and KIP models, whereas clozapine was effective on some cognitive symptoms such as reversal learning and novel object recognition [4, 34, 38, 39]. Although the function of PCP and ketamine as a NMDA receptor antagonist has been stressed, these drugs also bind to a variety of receptors [40]. Furthermore, the positive symptoms in PIP and KIP models were explained by an increase of dopamine level in the PFC, not by a hyper-glutamatergic state [31]. This increased dopamine level in the PFC can be explained by the affinity of ketamine at the dopamine receptor (ketamine acts as partial of D2 agonist), which is similar to that at the NMDA receptor [41]. However, in the case of PCP, the affinity at the 5-HT receptor is similar to that at the NMDA receptor, and its affinity at the dopamine D2 receptor is lower than both NMDA and 5-HT receptors [41]. Therefore, the explanation for the positive symptoms in the PIP and KIP models by dopamine transmission may be consistent with the amphetamine model, but further studies are needed to confirm its validity.

The PCP/ketamine model may be the most accessible model that shows schizophrenia-like behavior. However, since PCP and ketamine bind to various receptors, PIP and KIP have complex mechanisms underlying psychoses; which are further complicated by the absence of a concrete understanding of its mechanisms. Therefore, it is still uncertain whether PIP and KIP, with the assumption that they are based on the identical mechanism, will provide meaningful contributions to the study of schizophrenia.

**LSD induced psychosis**

LSD was synthesized for therapeutic purposes by Albert Hoffman. In 1938, he accidentally discovered the hallucinatory properties of LSD [7]. To date, LSD is the most powerful hallucinogen known that can distort the perception of time and space at very low doses compared to other drugs [6, 42, 43]. Due to its strong psychotomimetic effects, recreational use of the LSD has been increasing [44]. As a result, LSD has never been distributed for medicinal purposes, and has been illegally used. Although there are fewer studies on LSD compared to other drugs due to legal limitations, LSD was also presented as a drug of schizophrenia model when amphetamine induced psychosis received attention in the late twentieth century in schizophrenia studies [7].

There have been a significant number of studies that have investigated the psychosis induced by LSD. Across many of these studies, acute injection of LSD into animals at very low doses induced psychotic behaviors that were classified into positive symptoms [43], whereas chronic LSD administration with a low dosage (0.16 mg/kg) elicited positive symptoms as well as negative symptoms (Table 2) [42]. Such positive symptoms were hyper-locomotion and disrupted PPI. Negative symptoms were decreased social behavior and reduced sucrose preference (Table 1). It is interesting to note that the cognitive symptoms were not observed in the LSD induced psychosis animal model. Rather, cognitive function was improved by LSD. According to a paper by Hervey on the relation of serotonin receptors and learning, LSD injection at a dose of 0.013 mg/kg into rabbits enhanced associative learning [45, 46].

Although the specific mechanisms of action of LSD are not yet fully understood, numerous studies have pointed to the modulatory effect of LSD on the receptors of various systems including the serotonergic, dopaminergic systems, and to its affinity for 5-HT2A and dopamine D2 receptors as an starting point for investigation [47]. As a localization point for serotonergic neurons, the raphe nucleus projects to the thalamic regions. The agonist action of LSD on the 5-HT2A receptors of the thalamic afferents is responsible for the increase in glutamate levels in the corticocortical and corticosubcortical transmissions (Fig. 2) [48]. Thus, the usage of LSD has been shown to increase glutamate release onto the layer V pyramidal neurons of the PFC [49]. It appears that the elevated level of extracellular glutamate in the PFC region is associated with the symptoms of psychosis [42]. There are studies that test whether LSD-induced psychosis (LIP) is alleviated by antipsychotic drugs. Haloperidol failed to reverse disruption of PPI in the LIP model [43]. In contrast, hyperirritability, hyper-locomotion, anhedonia, and decreased social interaction were transiently reversed by haloperidol and olanzapine [42]. Olanzapine is an atypical antipsychotic drug and it has a higher affinity for 5-HT2A serotonin receptors than the D2 dopamine receptors [42]. Also, head-twitch response, a rapid side-to-side head movement, was alleviated by long term administration of clozapine in the LIP animal model [50].

LSD is a drug of weak addictive properties and at the same time is the most potent hallucinogen. In addition, LSD modulates the serotonergic, dopaminergic neurotransmission systems which are major targets of typical and atypical antipsychotics. Although this may indicate that the LIP model is most suitable for studying psychosis as it does not induce drug effects such as dependence of amphetamine and antidepressant effect of ketamine/ scopolamine. LSD enhances cognitive function. This means that LIP is, unfortunately, not adequate for schizophrenia research like the other four DIP models. Meanwhile, it also indicates that LIP is isolated set of symptoms that can be differentiated from schizophrenia.
Exhibited a hypofunction of NMDA receptors [58]. These recent dopamine turnover [60]. Mice with mutant human DISC1 as an increased affinity to dopamine D2 receptors and increased full length DISC1 showed altered dopamine homeostasis such as the mechanisms underlying psychotic behaviors of DIP. Animals with overexpressed transmission via downstream signaling of mGluR1 [70]. Interestingly, this regulation of neurotransmission is limited to adolescent mice (postnatal day 24–48), but not to adult mice. Systemic injection of ErbB kinase inhibitor into an adolescent mouse increases striatal dopamine levels, reduces sucrose consumption.

Disrupted-in-schizophrenia-1

It is known that Disrupted-in-schizophrenia-1 (DISC1) carries out multiple functions in coordination with numerous interacting partners. These partner proteins were mostly involved in axon elongation, radial migration, cortical development, and synaptic plasticity [54, 55]. Interestingly, although DISC1 is the most representative of the associated genes of schizophrenia, the expression of DISC1 in schizophrenics showed no difference with that in the healthy group [54]. Despite of the normal expression of DISC1 in schizophrenia patients, the mouse model overexpressing full-length human DISC1 showed abnormal wake/sleep patterns which were a characteristic of schizophrenia [56]. Whereas, reduced expression of proteins interacting with DISC1 was observed in the schizophrenia patients. Consistent with this data from patients, reduced interaction between DISC1 and PDE4B, a partner protein of DISC1, was also observed in two schizophrenia models that had a point mutation (Q31L and L100P, respectively) within the DISC1 sequence. However, interestingly, these two transgenic mice did not exhibit symptoms that covered the entire psychosis spectrum of schizophrenia. Mice with mutations of Q31L exhibited deficit in the forced swim test, whereas L100P mice showed impaired PPI and impaired latent inhibition [55, 57].

DISC1 contributes to these schizophrenic behaviors by affecting neurotransmission and brain development. According to recent studies, DISC1 was involved in dopamine and glutamate transmissions [58–60], which overlaps with mechanisms that underlie psychotic behaviors of DIP. Animals with overexpressed full length DISC1 showed altered dopamine homeostasis such as an increased affinity to dopamine D2 receptors and increased dopamine turnover [60]. Mice with mutant human DISC1 exhibited a hypofunction of NMDA receptors [58]. These recent results suggest that the roles of DISC1 in neurotransmission are similar to the dopamine and glutamate transmissions in AIP and PIP/KIP, respectively. Whereas, the fact that DISC1 affects brain development emphasizes the distinction of DIP. DISC1 is a scaffold protein that is associated with synaptic pruning, astrogenesis, cortical development, and hippocampal development [61–64]; processes which continue until adolescence. Consistent with the roles DISC1 is presumed to be involved in, administration of immune-stimulants into pregnant DISC1 L100P heterozygous mice induced schizophrenic behaviors [65], which suggest that genetic factors of schizophrenia were continuously affected by environmental factors during the developmental period. Therefore, the schizophrenia model has not only commonalities but also differences with the DIP models.

Neuregulin 1

Pro-neuregulin is a transmembrane protein that contains extracellular epidermal growth factor (EGF) domains. The pro-neuregulin 1 undergoes proteolytic cleavage by three transmembrane proteases (ADAM17, BACE, and ADAM19) [66] forming Neuregulin (Nrg 1), and of which binds to the ErbB4 receptor. Previous studies have associated Nrg 1 with synaptic plasticity, neurotransmitter transmission, and nervous system development [67, 68]. However, there have been inconsistencies in certain studies that the expression of these two proteins was either decreased or increased in the brain of patients with schizophrenia [66, 69]. In addition, there are many kinds of mouse models of which Nrg 1 is genetically engineered due to its numerous isoforms (at least 31 isoforms) and its multiple cleavage sites [66]. Among isoforms of Nrg 1, cysteine-rich domain Nrg 1 isoform is the most prominent neuregulin 1 variant in the brain, and mice overexpressing this isoform showed elevated anxiety and reduced PPI [69]. While, hyper-locomotion and reduced PPI were observed in mice with deletions of the Nrg 1 EGF domain and of the transmembrane domain of Nrg 1 [55, 67].

Nrg 1 contributes to schizophrenic behaviors via various mechanisms which may overlap or are completely separate with the mechanisms of DIP. These two mechanisms of Nrg 1 are connected with each other intricately. Likewise with the DIP models, the schizophrenia associated Nrg 1 is also involved in dopamine transmission. Nrg 1 and ErbB4 receptors expressed on membrane of dopaminergic neurons modulate dopaminergic transmission via downstream signaling of mGluR1 [70]. Interestingly, this regulation of neurotransmission is limited to adolescent mice (postnatal day 24–48), but not to adult mice. Systemic injection of ErbB kinase inhibitor into an adolescent mouse increases striatal dopamine levels, reduces sucrose consumption.
preference, and induces deficit in the T-maze reversal learning task later during adulthood [71]. In addition, neonatal Nrg 1 injection into mice induced altered properties of the dopaminergic neuron at an adult stage [72]. Together, schizophrenia and DIP share altered neurotransmission as a contributor to schizophrenia. Also, whereas causative factors of schizophrenia affect emergence of schizophrenic behaviors for a long period, drugs of DIP quickly act on the emergence of psychotic behaviors.

**Dysbindin**

Dysbindin is primarily located on axonal bundles and axonal terminals [73], and regulates neurotransmitter release in the presynaptic neuron while playing a role in receptor trafficking in the postsynaptic neuron [74, 75]. The expression of dysbindin is decreased in the PFC and the hippocampus of schizophrenia patients [76, 77]. Furthermore, reduced dysbindin expression was observed in dysbindin mutant mice, and these mice showed a decrease in NMDA-dependent glutamate receptor signaling and exhibited impaired working memory [78]. Whereas mice overexpressing human dysbindin exhibited increased locomotion by acute amphetamine administration [75].

How dysbindin affects schizophrenic behaviors can be explained by altered neurotransmission, in particular by dopaminergic transmission [79, 80]. Increased number of dopamine D2 receptors on the cell membrane was observed in Sandy (Sdy) mice with a mutation in the DTNBP1 gene that resulted in the reduced expression of dysbindin protein [79, 81]. In addition, effects of D2 receptor antagonists have been examined. Unsurprisingly, schizophrenia-like behaviors such as hyperactivity, impaired working memory, and spatial memory deficit were rescued by D2 receptor antagonists in the Sdy mouse model. However, this rescue effect was limited to the adolescent period (postnatal day 21~35 in mice) [79]. These results indicate that dysbindin plays a role in regulating functions of the dopamine D2 receptor. Furthermore, mutation in the DTNBP1 gene inhibits D2 receptors on the mPFC GABAergic neurons, resulting in an altered glutamatergic system [82]. In conclusion, mechanisms of schizophrenia based on dysbindin mutation also partially share those of DIP, especially in neurotransmission. Schizophrenic behaviors resulting from dysbindin mutation are expressed depending on the developmental stage of the animal.

**CONCLUSION**

Schizophrenia and DIP cannot be differentiated simply through observing symptoms. This implies that common mechanisms underlie schizophrenia and DIP and it is due to this that the DIP model was used in schizophrenia research. While previous studies have converged on the similarities of DIP and schizophrenia, in this review we aim to focus on the differences between the DIP and schizophrenia models. In terms of etiology and mechanisms, it is clear that DIP and schizophrenia are isolated. To specify, DIP is caused by drugs and schizophrenia is thought to develop due to genetic causes, indicating different mechanisms underlying their psychotic or schizophrenic behaviors. Also, most DIP studies have explained psychotic symptoms by altered neurotransmitter systems, whereas most schizophrenia model studies have described schizophrenic symptoms based on functional changes of genes identified from schizophrenia patients. Knowing the distinction between the DIP and schizophrenia models will inevitably reduce misinterpretation of results in future studies that utilize DIP models in schizophrenia research. Along with distinguishing animal models, further studies should focus on discovering the exact mechanisms for specific symptoms stemming from either drugs or genetic factors, which may provide a more effective treatment of drug induced psychosis or schizophrenia.

**ACKNOWLEDGEMENTS**

This research was funded by the National Research Council of Science & Technology (NST) grant by the Korean government (MSIP) (No. CRC-15-04-KIST).

**REFERENCES**

1. Dean K, Murray RM (2005) Environmental risk factors for psychosis. Dialogues Clin Neurosci 7:69-80.
2. Tenn CC, Fletcher PJ, Kapur S (2003) Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res 64:103-114.
3. Barak S, Weiner I (2007) Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology 32:989-999.
4. Chatterjee M, Ganguly S, Srivastava M, Palit G (2011) Effect of ‘chronic’ versus ‘acute’ ketamine administration and its ‘withdrawal’ effect on behavioural alterations in mice: implications for experimental psychosis. Behav Brain Res 216:247-254.
5. Castañé A, Santana N, Artigas F (2015) PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments. Psychopharmacology (Berl) 232:4085-4097.
6. Martin DA, Marona-Lewicka D, Nichols DE, Nichols CD (2014) Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology 83:1-8.
7. Murray RM, Paparelli A, Morrison PD, Marconi A, Di Forti M (2013) What can we learn about schizophrenia from studying the human model, drug-induced psychosis? Am J Med Genet B Neuropsychiatr Genet 162B:661-670.
8. Insel TR (2010) Rethinking schizophrenia. Nature 468:187-193.
9. Jones CA, Watson DJ, Fone KC (2011) Animal models of schizophrenia. Br J Pharmacol 164:1162-1194.
10. Fischer M (1971) Psychoses in the offspring of schizophrenic monozygotic twins and their normal co-twins. Br J Psychiatry 118:43-52.
11. Fatemi SH, Folsom TD (2009) The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 35:528-548.
12. Murphy CA, Fend M, Russig H, Feldon J (2001) Latent inhibition, but not prepulse inhibition, is reduced during withdrawal from an escalating dosage schedule of amphetamine. Behav Neurosci 115:1247-1256.
13. Russig H, Murphy CA, Feldon J (2002) Clozapine and haloperidol reinduce latent inhibition following its disruption during amphetamine withdrawal. Neuropsychopharmacology 26:765-777.
14. Russig H, Murphy CA, Feldon J (2003) Prepulse inhibition during withdrawal from an escalating dosage schedule of amphetamine. Psychopharmacology (Berl) 169:340-353.
15. Stefani MR, Moghaddam B (2002) Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res 134:267-274.
16. Featherstone RE, Rizos Z, Kapur S, Fletcher PJ (2008) A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. Behav Brain Res 189:170-179.
17. Hsieh JH, Stein DJ, Howells FM (2014) The neurobiology of methamphetamine induced psychosis. Front Hum Neurosci 8:537.
18. Bay-Richter C, O’Callaghan MJ, Mathur N, O’Tuathaigh CM, Heery DM, Fone KC, Waddington JL, Moran PM (2013) D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors. Neuropsychopharmacology 38:1512-1520.
19. Nagai T, Yamada K (2010) Molecular mechanism for methamphetamine-induced memory impairment. Nihon Arukoru Yakubutsu Igakkai Zasshi 45:81-91.
20. Riedel G, Kang SH, Choi DY, Platt B (2009) Scopolamine-induced deficits in social memory in mice: reversal by donepezil. Behav Brain Res 204:217-225.
21. Singer P, Yee BK (2012) Reversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice. Pharmacol Biochem Behav 101:107-114.
22. Barak S (2009) Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome. Behav Brain Res 204:335-351.
23. Benarroch EE (2012) Effects of acetylcholine in the striatum. Recent insights and therapeutic implications. Neurology 79:274-281.
24. Forster GL, Blaha CD (2000) Laterodorsal tegmental stimulation elicits dopamine efflux in the rat nucleus accumbens by activation of acetylcholine and glutamate receptors in the ventral tegmental area. Eur J Neurosci 12:3596-3604.
25. Yeomans JS (1995) Role of terminal cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 12:3-16.
26. Fendt M, Li L, Yeomans JS (2001) Brain stem circuits mediating prepulse inhibition of the startle reflex. Psychopharmacology (Berl) 156:216-224.
27. Jones GH, Mittleman G, Robbins TW (1989) Attenuation of amphetamine-stereotypy by mesortrial dopamine depletion enhances plasma corticosterone: implications for stereotypy as a coping response. Behav Neurol Biol 51:80-91.
28. Navarria A, Wohleh ES, Voleti B, Ota KT, Dutheil S, Lepack AE, Dwyer JM, Fuchikami M, Becker A, Drago F, Duman RS (2015) Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurol Dis 82:254-261.
29. Frohlich J, Van Horn JD (2014) Reviewing the ketamine model for schizophrenia. J Psychopharmacol 28:287-302.
30. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-467.
31. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927.
32. Kalinichev M, Robbins MI, Hartfield EM, Maycox PR, Moore SH, Savage KM, Austin NE, Jones DN (2008) Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity
and gene induction study. Prog Neuropsychopharmacol Biol Psychiatry 32:414-422.

33. Egerton A, Reid L, McKechar CE, Morris BJ, Pratt JA (2005) Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl) 179:77-84.

34. Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J (2008) Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33:2657-2666.

35. Rushforth SL, Steckler T, Shoaib M (2011) Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure. Neuropsychopharmacology 36:2774-2781.

36. Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27:11496-11500.

37. Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL (2006) Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. McGraw-Hill, New York, NY.

38. Grayson B, Idris NF, Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184:31-38.

39. Abdul-Monim Z, Reynolds GP, Neill JC (2006) The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 169:263-273.

40. Sleight J, Harvey M, Voss L, Denny B (2014) Ketamine: more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care 4:76-81.

41. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2A) receptors: implications for models of schizophrenia. Mol Psychiatry 7:837-844.

42. Marona-Lewicka D, Nichols CD, Nichols DE (2011) An animal model of schizophrenia based on chronic LSD administration: old idea, new results. Neuropsychopharmacology 61:503-512.

43. Ouagazzal A, Grottick AJ, Moreau J, Higgins GA (2001) Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 25:565-575.

44. Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ (2016) Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci USA 113:4853-4858.

45. Harvey JA (2003) Role of the serotonin 5-HT(2A) receptor in learning. Learn Mem 10:355-362.

46. Harvey JA, Gormezano I, Cool-Hauser VA, Schindler CW (1988) Effects of LSD on classical conditioning as a function of CS-UCS interval: relationship to reflex facilitation. Pharmacol Biochem Behav 30:433-441.

47. De Gregorio D, Comai S, Posa L, Gobbi G (2016) d-Lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology. Int J Mol Sci 17:E1953.

48. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14:295-314.

49. Burt DR, Creese I, Snyder SH (1976) Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Mol Pharmacol 12:631-638.

50. Moreno JL, Holloway T, Umani A, Rayannavar V, Sealfon SC, Gonzalez-Maeso J (2013) Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice. Psychopharmacology (Berl) 225:217-226.

51. McGuffin P, Tandon K, Corsico A (2003) Linkage and association studies of schizophrenia. Curr Psychiatry Rep 5:121-127.

52. Riley B, Kendler KS (2006) Molecular genetic studies of schizophrenia. Eur J Hum Genet 14:669-680.

53. Ripke S, O’Dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, Bergen SE, Collins AL, Crowley JJ, Fromer M, Kim Y, Lee SH, Magnusson PK, Sanchez N, Stahl EA, Williams S, Wray NR, Xia K, Bettella F, Borglum AD, Bulik-Sullivan BK, Cormican P, Craddock N, de Leeuw C, Durmishi N, Gill M, Goliemt V, Hamshere ML, Holmans P, Hougaard DM, Kendler KS, Lin K, Morris DW, Mors O, Mortensen PB, Neale BM, O’Neill FA, Owen MJ, Milovanovicic MP, Posthumaa D, Powell J, Richards AL, Riley BP, Rudfer D, Rujescu D, Sigurdsson E, Silagadze T, Smit AB, Stefansson H, Steinberg S, Suvisaari J, Tosato S, Verhage M, Walters JT, Levinson DF, Gejman PV, Kendler KS, Laurent C, Mowry BJ, O’Donovan MC, Owen MJ, Pulver AE, Riley BP, Schwab SG, Wildenauer DB, Dudbridge F, Holmans P, Shi J, Albus M, Alexander M, Campion D, Cohen D, Dikeos D, Duan J, Eichhammer P, Godard S, Hansen M, Lerer FB, Liang KY, Maier W, Mallet J, Nertney DA, Nestadt G, Norton N, O’Neill FA, Papadimitriou
GN, Ribbe R, Sanders AR, Silverman JM, Walsh D, Williams NM, Wormley B, Arranz MJ, Bakker S, Bender S, Bramon E, Collier D, Crespo-Facorro B, Hall J, Iyegbe C, Jablensky A, Kahn RS, Kalaydjieva L, Lawrie S, Lewis CM, Lin K, Linszen DH, Mata I, McIntosh A, Murray RM, Ophoff RA, Powell J, Rujescu D, Van Os J, Walshe M, Weisbrod M, Wiersma D, Donnelly P, Barroso I, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin AP, Deloukas P, Duncanson A, Jankowski J, Markus HS, Mathew CG, Palmer CN, Plomin R, Rautanen A, Sawyer S, Trembath RC, Viswanathan AC, Wood NW, Spencer CC, Band G, Bellenguez C, Freeman C, Hellenthal G, Giannoulatou E, Pirinen M, Pearson RD, Strange A, Su Z, Vukcevic D, Donnelly P, Langford C, Hunt SE, Edkins S, Gwilliam R, Blackburn H, Bumpstead SJ, Dronov S, Gillman M, Gray E, Hammond N, Jayakumar A, McCann OT, Liddle J, Potter SC, Ravindrarajah R, Ricketts M, Tashakkori-Ghanbaria A, Waller MJ, Weston P, Widaa S, Whittaker P, Barroso I, Deloukas P, Mathew CG, Blackwell JM, Brown MA, Corvin AP, McCarthy MI, Spencer CC, Bramon E, Corvin AP, O’Donovan MC, Stefansson K, Scolnick E, Purcell S, McCarroll SA, Sawa A, Straub RE, Mitkus S, Weickert CS, Matsumoto M, Sawa A, Straub RE, Vakkalanka R, Herman MM, Weinberger DR, Kleinman JE (2006) Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum Mol Genet 15:1245-1258.

54. Lipska BK, Peters T, Hyde TM, Halim N, Horowitz C, Mitkus S, Weickert CS, Matsumoto M, Sawa A, Straub RE, Vakkalanka R, Herman MM, Weinberger DR, Kleinman JE (2006) Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum Mol Genet 15:1245-1258.

55. Jaaro-Peled H (2009) Gene models of schizophrenia: DISC1 mouse models. Prog Brain Res 179:75-86.

56. Jaaro-Peled H, Altimus C, LeGates T, Cash-Padgett T, Zoubovsky S, Hikida T, Ishizuka K, Hattar S, Mongrain V, Porteous DJ, Roder JC (2007) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54:387-402.

57. Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, Lerch JP, Trimble K, Uchiyama M, Sakuraba Y, Kaneda H, Shiroishi T, Houslay MD, Henkelman RM, Sled JG, Gondo Y, Porteous DJ, Roder JC (2007) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54:387-402.

58. Ma TM, Abazyan S, Abazyan B, Nomura J, Yang C, Seshadri S, Sawa A, Snyder SH, Pletnikov MV (2013) Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. Mol Psychiatry 18:557-567.

59. Su P, Li S, Chen S, Lipina TV, Wang M, Lai TK, Lee FH, Zhang H, Zhai D, Ferguson SS, Nobrega JN, Wong AH, Roder JC, Fletcher PJ, Liu F (2014) A dopamine D2 receptor-DISC1 protein complex may contribute to antipsychotic-like effects. Neuron 84:1302-1316.

60. Trossbach SV, Bader V, Hecher L, Pum ME, Masoud ST, Prikulis I, Schäble S, de Souza Silva MA, Su P, Boulat B, Chwiesko C, Poschmann G, Stühler K, Lohr KM, Stout KA, Oskamp A, Godsave SF, Müller-Schiffmann A, Bilzer T, Steiner H, Peters PJ, Bauer A, Sauvage M, Ramsey AJ, Miller GW, Liu F, Seeman P, Brandon NJ, Hunston JP, Korth C (2016) Misassembly of full-length Disrupted-in-Schizophrenia 1 protein is linked to altered dopamine homeostasis and behavioral deficits. Mol Psychiatry 21:1561-1572.

61. Narayan S, Nakajima K, Sawa A (2013) DISC1: a key lead in studying cortical development and associated brain disorders. Neuroscientist 19:451-464.

62. Tomita K, Kubo K, Ishii K, Nakajima K (2011) Disrupted-in-Schizophrenia-1 (Disc1) is necessary for migration of the pyramidal neurons during mouse hippocampal development. Hum Mol Genet 20:2834-2845.

63. Wang S, Liang Q, Qiao H, Li H, Shen T, Ji F, Jiao J (2016) DISC1 regulates astrogenesis in the embryonic brain via modulation of RAS/MEK/ERK signaling through RASSF7. Development 143:2732-2740.

64. Hayashi-Takagi A, Barker PB, Sawa A (2011) Readdressing synaptic pruning theory for schizophrenia: combination of brain imaging and cell biology. Commun Integr Biol 4:211-212.

65. Lipina TV, Zai C, Hlousek D, Roder JC, Wang S, Liang Q, Qiao H, Li H, Shen T, Ji F, Jiao J (2016) DISC1 regulates astrogenesis in the embryonic brain via modulation of RAS/MEK/ERK signaling through RASSF7. Development 143:2732-2740.

66. Meier I, Xiong WC (2008) Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9:437-452.

67. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsdottir T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalez A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Tulcher JR, Petursson H, Stefansson K (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877-892.

68. Harrison PJ, Law AJ (2006) Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60:132-140.
69. Agarwal A, Zhang M, Trembak-Duff I, Unterbarscheit
T, Radychuk K, Dibaj P, Martins de Souza D, Boretius S,
Brzózka MM, Steflens H, Berning S, Teng Z, Gummert MN,
Tantara M, Guest PC, Willig KI, Frahm J, Hell SW, Bahn S,
Rossner MJ, Nave KA, Ehrenreich H, Zhang W, Schwab MH
(2014) Dysregulated expression of neuregulin-1 by cortical
pyramidal neurons disrupts synaptic plasticity. Cell Rep
8:1130-1145.
70. Ledonne A, Nobili A, Latagliata EC, Cavallucci V,
Guatteo E, Puglisi-Allegra S, D’Amelio M, Mercuri NB
(2015) Neuregulin 1 signalling modulates mGluR1 function
in mesencephalic dopaminergic neurons. Mol Psychiatry
20:959-973.
71. Golani I, Tadmor H, Buonanno A, Kremer I, Shamir A
(2014) Disruption of the ErbB signaling in adolescence increases
striatal dopamine levels and affects learning and hedonic-like
behavior in the adult mouse. Eur Neuropsychopharmacol
24:1808-1818.
72. Namba H, Okubo T, Nawa H (2016) Perinatal exposure
to neuregulin-1 results in disinhibition of adult midbrain
dopaminergic neurons: implication in Schizophrenia
modeling. Sci Rep 6:22606.
73. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake
DJ (2001) Dysbindin, a novel coiled-coil-containing protein
that interacts with the dystrobrevins in muscle and brain. J
Biol Chem 276:24232-24241.
74. Bhardwaj SK, Ryan RT, Wong TP, Srivastava LK (2015)
Loss of dysbindin-1, a risk gene for schizophrenia, leads to impaired
group 1 metabotropic glutamate receptor function in mice.
Front Behav Neurosci 9:72.
75. Shintani N, Onaka Y, Hashimoto R, Takamura H, Nagata T,
Umeda-Yano S, Mouri A, Mamiya T, Haba R, Matsuzaki S,
Katayama T, Yamamori H, Nakazawa T, Nagayasu K, Ago Y,
Yagasaki Y, Nabeshima T, Takeda M, Hashimoto H (2014)
Behavioral characterization of mice overexpressing human
dysbindin-1. Mol Neurobiol 7:74.
76. Weickert CS, Straub RE, McClintock BW, Matsumoto M,
Hashimoto R, Hyde TM, Herman MM, Weinberger DR,
Kleinman JE (2004) Human dysbindin (DTNBP1) gene
expression in normal brain and in schizophrenic prefrontal
cortex and midbrain. Arch Gen Psychiatry 61:544-555.
77. Weickert CS, Rothmond DA, Hyde TM, Kleinman JE, Straub
RE (2008) Reduced DTNBP1 (dysbindin-1) mRNA in the
hippocampal formation of schizophrenia patients. Schizophr
Res 98:105-110.
78. Karlsgödt KH, Robleto K, Trantham-Davidson H, Jairl C,
Cannon TD, Lavin A, Jentsch JD (2011) Reduced dysbindin
expression mediates N-methyl-D-aspartate receptor
hypofunction and impaired working memory performance.
Biol Psychiatry 69:28-34.
79. Jia JM, Zhao J, Hu Z, Lindberg D, Li Z (2013) Age-dependent
regulation of synaptic connections by dopamine D2
receptors. Nat Neurosci 16:1627-1636.
80. Yin DM, Xiong WC, Mei L (2013) Adolescent dopamine
slows spine maturation. Nat Neurosci 16:1514-1516.
81. Iizuka Y, Sei Y, Weinberger DR, Straub RE (2007) Evidence
that the BLOC-1 protein dysbindin modulates dopamine
D2 receptor internalization and signaling but not D1
internalization. J Neurosci 27:12390-12395.
82. Ji Y, Yang F, Papaleo F, Wang HX, Gao WJ, Weinberger DR, Lu
B (2009) Role of dysbindin in dopamine receptor trafficking
and cortical GABA function. Proc Natl Acad Sci U S A
106:19593-19598.
83. Castner SA, Vosler PS, Goldman-Rakic PS (2005)
Amphetamine sensitization impairs cognition and reduces
dopamine turnover in primate prefrontal cortex. Biol
Psychiatry 57:743-751.
84. Der-Avakian A, Markou A (2010) Withdrawal from chronic
exposure to amphetamine, but not nicotine, leads to an
immediate and enduring deficit in motivated behavior
without affecting social interaction in rats. Behav Pharmacol
21:359-368.
85. Andriambeloson E, Huyard B, Poiraud E, Wagner S (2014)
Methyllycaconitine- and scopolamine-induced cognitive
dysfunction: differential reversal effect by cognition-
enhancing drugs. Pharmacol Res Perspect 2:e00048.
86. Chindo BA, Adzu B, Yahaya TA, Gamaniel KS (2012)
Ketamine-enhanced immobility in forced swim test: a
possible animal model for the negative symptoms of
schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry
38:310-316.
87. Koványi B, Csölle C, Calovi S, Hanuska A, Kató E, Köles L,
Bhattacharya A, Haller J, Sperlágh B (2016) The role of P2X7
receptors in a rodent PCP-induced schizophrenia model. Sci
Rep 6:36680.
88. O’Tuathaigh CM, Babovic D, O’Sullivan GJ, Clifford JJ, Tighe
O, Croke DT, Harvey R, Waddington JL (2007) Phenotypic
characterization of spatial cognition and social behavior
in mice with ‘knockout’ of the schizophrenia risk gene
neuregulin 1. Neuroscience 147:18-27.
89. Schumacher A, Sivanandan B, Tolledo EC, Wolde Gabriel J,
Itô R (2016) Different dosing regimens of repeated ketamine
administration have opposite effects on novelty processing in
rats. Prog Neuropsychopharmacol Biol Psychiatry 69:1-10.